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Abstract
Despite growing research interest in the pathophysiology of heart failure with
preserved ejection fraction (HFpEF), it remains unknown whether central
hemodynamic alterations inherently present in this condition do affect blood
pressure and blood volume (BV) regulation. The present study sought to deter-
mine hemodynamic and endocrine responses to prolonged orthostatic stress in
HFpEF patients. Central venous pressure (CVP) assessed via the internal jugular
vein (IJV) aspect ratio with ultrasonography, arterial pressure and heart rate
were determined at supine rest and during 2 hours of moderate (25–30) head-
up tilt (HUT) in 18 stable HFpEF patients (71.2  7.3 years), 14 elderly (EC),
and 10 young (YC) healthy controls. Parallel endocrine measurements com-
prised main BV-regulating hormones: pro-atrial natriuretic peptide, copeptin,
aldosterone, and erythropoietin (EPO). At supine rest, the IJV aspect ratio was
higher (>30%) in HFpEF patients compared with EC and YC, while mean arte-
rial pressure was elevated in HFpEF patients (98.0  13.1 mm Hg) and EC
(95.6  8.3 mm Hg) versus YC (87.3  5.0 mm Hg) (P < 0.05). HUT
increased heart rate (+10%) and reduced the IJV aspect ratio (52%), with
similar hemodynamic effects in all groups (P for interaction ≥ 0.322). The anal-
ysis of endocrine responses to HUT revealed a group9time interaction for cir-
culating EPO, which was increased in YC (+10%) but remained unaltered in
HFpEF patients and EC. The EPO response to a given reduction in CVP is sim-
ilarly impaired in HFpEF patients and elderly controls, suggesting an age-
dependent dissociation of EPO production from hemodynamic regulation in
the HFpEF condition.
Introduction
The condition of heart failure with preserved ejection frac-
tion (HFpEF) entails prominent hemodynamic alterations
challenging the pressure gradient driving venous return as
well as the regulation of blood volume (BV) (Miller 2016;
Montero et al. 2017). A fairly constant BV in healthy
humans depends on stretch receptors located predomi-
nantly in the atria and veno-atrial junctions where they
sense central venous pressure (CVP), which reflects the
filling state of the cardiovascular system (Guyton 1957;
Gauer and Henry 1963). BV-regulating hormones are
released in response to changes in CVP via autonomic
pathways (Segar and Moore 1968; Egan et al. 1984; Bie
et al. 1986; Sander-Jensen et al. 1986; Montero et al.
2016a). These hormones control the two major con-
stituents of BV, that is, plasma volume (PV) and red blood
cell volume (RBCV) (Montero et al. 2016a). A reduction in
CVP induced by either moderate blood loss or head-up tilt
(HUT) activates the renin–angiotensin–aldosterone system
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(RAAS) and enhances the production of vasopressin and
erythropoietin (EPO) (Ehmke et al. 1995; Roberts et al.
2000; Montero et al. 2016a), the principal hormones regu-
lating fluid homeostasis and erythropoiesis, respectively.
On the other hand, infusion of BV expanders or sustained
head-down tilt leading to increased CVP prompts the
release of natriuretic peptides by atrial cells in parallel to
decreasing circulating EPO levels (Gunga et al. 1996; Brey-
mann et al. 2000) eventually resulting in substantial reduc-
tions in PV and RBCV (Fortney et al. 1994). Therefore, in
the presence of a chronic increase in CVP and possibly
altered stretch receptor sensitivity due to cardiovascular
stiffening, as is indeed characteristic of HFpEF patients
(Guazzi et al. 2011; Reddy and Borlaug 2016; Redfield
2016), the regulation of BV could be compromised. In this
regard, recent investigations underline the clinical relevance
of fluid dysregulation and the need to reassess the complex
pathophysiology of congestion in the HFpEF condition
(Miller 2016; Miller and Mullan 2016; Montero et al.
2017). The impairment of central pressure/volume sensors
could primarily contribute to endocrine-related specific
alterations in PV as well as RBCV in HFpEF patients
(Miller 2016; Montero et al. 2016b; Montero et al. 2017).
This would concur with the high prevalence of true anemia
(RBCV deficit) in HFpEF cohorts along with the inverse
linear relationship between BV and ejection fraction in the
heart failure population (Montero et al. 2017). Yet, rela-
tively little is currently known regarding the hemodynamic
and endocrine regulation of intravascular volume in the
HFpEF condition. Integrative experimental research
designed to pinpoint hemodynamic and endocrine
responses to changes in CVP may provide sound evidence,
but to our knowledge, this remains to be materialized.
The present study experimentally assessed for the first
time whether central hemodynamic alterations inherently
present in the HFpEF condition alter blood pressure and
BV regulation during an orthostatic challenge. Specifically,
the purpose of this study was to assess the impact of pro-
longed moderate HUT on central hemodynamics and
major BV-regulating hormones in stable HFpEF patients
and healthy controls including age-matched elderly (EC)
and young (YC) individuals. We hypothesized that hemo-
dynamic and endocrine responses to reduced CVP will be
impaired in HFpEF patients compared with control indi-
viduals, independently of the age status.
Methods
Ethical approval
The study was approved by the Ethical Commission of
Zurich (BASEC-Nr. 2016-02167, KEK-ZH-Nr. 2015-0044)
and conducted in accordance with the declaration of
Helsinki. Prior to the start of the experiments, informed
oral and written consents were obtained from all
participants.
Study population
Stable HFpEF patients (left ventricular ejection fraction
(LVEF) = 55.7  4.9%) were recruited from the HF out-
patient clinic of the University Hospital of Zurich. Inclu-
sion criteria comprised: signs and symptoms of HF
(Ponikowski et al. 2016), LVEF > 50%, elevated levels of
N-terminal pro b-type natriuretic peptide (NT-
proBNP > 125 pgmL1), relevant structural/functional
cardiac alterations, and no history of iron-deficiency ane-
mia. Healthy age- and sex-matched individuals (EC) were
recruited from the community and excluded if they pre-
sented any chronic medical illness, were taking daily pre-
scription medications, had current medical symptoms, or
were performing aerobic exercise on a regular basis. An
additional group of healthy young control individuals (YC)
enrolled in a parallel investigation (Montero et al. 2016a)
were included in order to determine the influence of age.
Experimental design
The tilt-table test was performed after fasting overnight in
a quiet room with controlled temperature between 22 and
24°C. Patient’s regular medication remained unaltered
before study assessments. Following 15 min of supine rest,
patients were tilted to 25–30° (i.e., HUT) for 120 min. A
climbing harness (bicycle saddle for YC) gently held the
body weight of individuals at the hip level throughout the
HUT protocol. Hemodynamic variables and blood samples
were obtained at supine rest and discrete time points (20,
60, and 120 min) during HUT. Blood samples at the last
time point (120 min) were not available in YC due to
specific protocol characteristics. All blood samples were
centrifuged and stored at 80°C until analyzed.
Experimental measures
Hemodynamics
The internal jugular vein (IJV) aspect ratio, a surrogate
marker of central venous pressure (CVP), was determined
at the level of the cricoid cartilage using the method
described by Keller et al. (2009). In brief, the left IJV was
assessed by means of a 7-MHz linear array probe attached
to a high-resolution ultrasound device (SonixTouch, BK
Ultrasound, USA). After obtaining an optimized IJV
image, a 20-s B-mode cine loop was obtained and
reviewed frame by frame to identify the largest cross-
sectional area (during expiration), and vessel dimensions
2019 | Vol. 7 | Iss. 5 | e14021
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were recorded. The IJV height was divided by its width to
obtain the aspect ratio. Systemic arterial pressure was
measured on the arm with an automated system (Micro-
life BP3AC1-1PC, Omron, Switzerland). In addition,
pulse wave analysis (PWA) was performed on radial
artery pressure waveforms (SphygmoCor, AtCor Medical,
Australia) and carotid artery distensibility was determined
by means of high-resolution ultrasound (SonixTouch, BK
Ultrasound, USA) (Van Bortel et al. 2002). The distensi-
bility coefficient (DC) was calculated according to the fol-
lowing formula:
DC ¼ ð2DD Dþ DD2Þ=ðPP D2Þ
where D is arterial diameter, ΔD is distension, and PP is
pulse pressure. DC represents the reciprocal value of arte-
rial stiffness.
Laboratory parameters
Blood samples (5 mL) from the antecubital vein were col-
lected anaerobically in heparinized glass syringes. Serum
creatinine was measured via the kinetic Jaffe reaction
(Hitachi P-Modular system, Roche Diagnostics, Switzer-
land) and glomerular filtration rate (eGFR) was calculated
by the CKD-EPI Creatinine Equation (2009) according to
guidelines from the National Kidney Foundation (Inker
et al. 2014). Hormones measured in plasma included pro-
ANP, N-terminal pro-b-type natriuretic peptide (NT-
proBNP), aldosterone, erythropoietin, and copeptin
(Morgenthaler 2010; Balanescu et al. 2011; Roussel et al.
2014), which is the carboxy-terminal portion of the pre-
cursor of vasopressin used as a surrogate clinical marker
owing to its greater stability and reliability (Morgenthaler
et al. 2006, 2008). Pro-atrial natriuretic peptide (pro-
ANP) was assessed with a midregional assay on a Kryptor
Plus platform (Thermo-Fisher, Germany) (Hunter et al.
2011), while NT-proBNP was determined by immunoas-
say (Elecsys NT-proBNP, Roche Diagnostics, Switzerland).
Copeptin was assessed by means of an automated
immunofluorescent assay (Thermo Fisher Scientific
BRAHMS, Germany) (Balanescu et al. 2011; Roussel et al.
2014). A competitive enzyme immunoassay (R&D Sys-
tems Inc., USA) was used to determine aldosterone. EPO
was measured via the Human EPO Quantikine IVD
ELISA Kit (R&D Systems Inc., USA). Furthermore,
plasma albumin levels were assessed with ALB reagent in
conjunction with UniCel DxC 600/800 and Synchron
Systems Multi Calibrator (Beckman Coulter, USA).
Statistical analysis
Statistical analysis was performed using SPSS 22.0 (SPSS,
Chicago, IL). Data were tested for normal distribution
with the Kolmogorov–Smirnov test, homogeneity of vari-
ances with Levene’s test, and sphericity with Mauchly’s
test. Data not-normally distributed, violating the assump-
tions of homogeneity of variances and/or sphericity were
logarithmically transformed before parametric testing.
Fisher’s exact test and one-way ANOVA with Tukey post
hoc tests were used to compare baseline variables in
HFpEF patients and control individuals. Tilt-table experi-
ments were analyzed with two-way repeated measures
ANOVA with “time” and “group” as within- and
between-subject factors, respectively, along with the inter-
action among these factors. Pairwise comparisons were
performed using Student’s paired t test. Data are reported
as mean  SD unless otherwise stated. A two-tailed
P-value less than 0.05 (0.10 for interaction) (Durand
2013) was considered significant.
Results
Baseline characteristics
Table 1 presents anthropometrical and clinical character-
istics of HFpEF patients and control individuals. Body
mass index was elevated (P < 0.05) in HFpEF patients
compared with EC and YC. Sex distribution was similar
among groups. Kidney function, determined by eGFR,
was mildly reduced (P < 0.05) in HFpEF patients relative
to EC (data not available in YC). Comorbidities compris-
ing hypertension (78%), coronary artery disease (44%),
and diabetes mellitus (28%) were the most prevalent
among HFpEF patients. With respect to medication, beta-
blockers (67%), loop diuretics (61%), and angiotensin-
converting-enzyme inhibitors/angiotensin II-receptor
blockers (61%) were common and similarly prevalent.
Hemodynamic and endocrine variables at supine rest
are reported in Table 2. The IJV aspect ratio was elevated
(P < 0.05) in HFpEF patients compared with EC and YC,
while mean arterial pressure was augmented (P < 0.05) in
HFpEF patients and EC versus YC. No difference was
detected for aortic augmentation index and carotid artery
distensibility between HFpEF and EC (data not available
in YC). With respect to endocrine variables, all BV-
regulating hormones were elevated in HFpEF patients
compared with EC and/or YC.
Hemodynamic responses to head-up tilt
(HUT)
Figure 1 displays the effects of HUT on hemodynamic
variables in HFpEF patients and control individuals. As
expected, IJV aspect ratio was decreased throughout HUT
(P for time < 0.001), with a similar decline observed in
all groups (P for interaction = 0.322). No definite pattern
ª 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Table 1. Baseline characteristics of HFpEF patients and controls.
HFpEF EC YC
n 18 14 10
Age (years) 71.2  7.3 70.6  5.5 25.5  2.11,2
Sex (female/male) 5/13 2/12 0/10
Body mass index (kgm2) 28.9  4.5 24.8  3.31 22.7  1.31
Body surface area (m2) 1.94  0.24 1.91  0.18 1.95  0.09
NT-proBNP (ngL1) 859  758 81  431 ―
eGFR (mLmin1) 64.6  20.9 82.6  9.81 ―
Hct (%) 40  5 44  21 ―
Ferritin (lgL1) 149  103 195  115 ―
Albumin (gL1) 40.0  3.7 41.3  1.8 41.1  2.2
Smoking (yes/no) 3/18 0/15 0/10
Cardiac alterations (%)
LVH 28 01 01
LAE 78 01 01
Diastolic dysfunction 83 01 01
Atrial fibrillation 28 01 01
Comorbidities (%)
CAD 44 01 01
HTN 78 01 01
DM 28 01 01
Medication (%)
ACEI/ARB 61 01 01
BB 67 01 01
Loop DIU 61 01 01
Metformin 11 01 01
Statins 56 01 01
Data are presented as mean  SD, ratio or %. ACEI/ARB, angiotensin-converting-enzyme inhibitors or angiotensin II-receptor blockers; BB,
beta-blockers; CAD, coronary artery disease; DM, diabetes mellitus; EC, elderly controls; eGFR, estimated glomerular filtration rate; Hct, hema-
tocrit; HFpEF, heart failure with preserved ejection fraction; HTN, hypertension; LAE, left atrial enlargement; Loop DIU, loop diuretics; LVH, left
ventricular hypertrophy; NT-proBNP, N-terminal pro-b-type natriuretic peptide; YC, young controls; —, not available.
1Significantly different (P < 0.05) compared with HFpEF.
2Significantly different (P < 0.05) compared with EC.
Table 2. Hemodynamic and endocrine variables at supine rest in HFpEF patients and controls
HFpEF EC YC
Central hemodynamics
IJV aspect ratio 0.71  0.18 0.54  0.211 0.51  0.121
SBP (mm Hg) 138.2  22.7 135.6  15.9 122.0  7.3
PP (mm Hg) 60.2  18.7 59.8  18.4 59.5  3.5
HR (bpm) 61.2  12.3 56.9  8.2 56.4  19.1
Aortic Aix@75 (%) 26.1  9.3 24.8  6.1 ―
Carotid distensibility (kPa1103) 1.6  0.7 2.1  1.2 ―
BV-regulating hormones
proANP (pmolL1) 274.8  185.8 133.7  41.01 39.6  12.21
Copeptin (pmolL1) 18.4  17.9 9.1  12.8 4.8  0.91
Aldosterone (ngdL1) 106.4  53.3 59.0  18.21 ―
EPO (UL1) 16.2  15.1 7.2  1.81 9.9  2.4
Data are presented as mean  SD. Aix@75, augmentation index adjusted by heart rate of 75 bpm; EC, elderly controls; EPO, erythropoietin;
HFpEF, heart failure with preserved ejection fraction; HR, heart rate; IJV, internal jugular vein; PP, pulse pressure; proANP, pro-atrial natriuretic
peptide; SBP, systolic blood pressure; YC, young controls; —, not available.
1Significantly different (P < 0.05) compared with HFpEF.
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was detected for systolic blood pressure (SBP) (P for
time = 0.369, P for interaction = 0.457), whereas PP was
reduced with HUT (P for time = 0.020, P for interac-
tion = 0.680). Conversely, heart rate was increased during
HUT (P for time = 0.045, P for interaction = 0.626).
None of the hemodynamic effects induced by HUT dif-
fered among groups. No sign/symptom of orthostatic
hypotension was observed in any individual.
Endocrine responses to head-up tilt (HUT)
The effects of HUT on BV-regulating hormones in
HFpEF patients and control individuals are presented in
Figure 2. In keeping with a typical response to reduced
CVP, proANP was decreased with HUT in all groups
(P for time < 0.001, P for interaction = 0.908). Likewise,
HUT increased copeptin (P for time = 0.015, P for inter-
action = 0.657) and aldosterone (P for time = 0.003 P for
interaction = 0.520) (data not available in YC). A group
9 time interaction was detected for EPO (P for interac-
tion = 0.061) in that EPO was only increased with HUT
in YC. No change in EPO during HUT was noted in
HFpEF patients and EC.
Discussion
This study assessed hemodynamic and endocrine
responses to HUT in stable HFpEF patients and healthy
controls comprising age-matched elderly (EC) and young
(YC) individuals. The main findings are: (1) HUT elicits
similar reductions in IJV aspect ratio and compensatory
increases in heart rate in HFpEF patients and control
individuals, irrespective of the age status; (2) circulating
EPO augments with HUT in YC but remains unaltered in
HFpEF patients and EC.
Since the inception of current concepts in cardiovascu-
lar physiology in the mid-20th century, the regulation of
the cardiovascular system has been intrinsically linked to
its internal volume, that is, BV (Guyton 1957; Gauer and
Henry 1963). A clear-cut example of this relationship is
evidenced by the ineludible impact of hemorrhage or BV
expansion on CVP and cardiac preload, key hemody-
namic variables determining stroke volume via the Frank–
Starling mechanism (Guyton and Hall 2011). In turn,
volumetrically induced changes in stroke volume are
counterbalanced with opposite changes in heart rate and
vascular resistance mediated by the autonomic nervous
system in order to maintain a steady cardiac output and
blood pressure (Robinson et al. 1966; Bonne et al. 2014).
Cardiovascular function is thus fundamentally regulated
by BV. Reciprocally, BV depends upon intact cardiovascu-
lar stretch receptors, also known as baroreceptors, signal-
ing the filling state of the low-pressure system (veins,
right heart, pulmonary circulation, left atrium; compris-
ing approximately 80% of BV) and high-pressure system
(left ventricle, arteries) to the medullary cardiovascular
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Figure 1. Hemodynamic responses to HUT in HFpEF patients and control individuals. Data are presented as mean  SEM. and control
individuals.* Significant change (P < 0.05) compared with baseline (supine). EC, elderly controls; HFpEF, heart failure with preserved ejection
fraction; HR, heart rate; HUT, head-up tilt; IJV, internal jugular vein; PP, pulse pressure; SBP, systolic blood pressure; YC, young controls.
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center (Segar and Moore 1968; Egan et al. 1984; Bie et al.
1986; Sander-Jensen et al. 1986; Montero et al. 2016a). In
HFpEF patients, baroreceptor dysfunction and abnormal
BV are expected as a result of chronically elevated CVP
levels and reduced cardiovascular distensibility (Guazzi
et al. 2011; Reddy and Borlaug 2016; Montero et al.
2017). These central phenotypic alterations may hinder
the intertwined regulation of blood pressure and volume,
including PV and RBCV components, which is a topic
being reexamined in light of new experimental evidence
in the heart failure field (Hage et al. 2015; Miller 2016;
Miller and Mullan 2016; Montero et al. 2016b; Montero
et al. 2017). Among the uncertainties, it is currently
unknown whether basic compensatory hemodynamic
responses to altered BV distribution are impaired in this
condition. Our findings indicate that central hemody-
namic effects induced by 2 h of HUT, which led to an
estimated ~3 mmHg decrease in CVP (Prekker et al.
2013) equivalent to 10% BV loss and 50% reduction in
baroreceptor firing rate (Gauer and Henry 1963), and do
not differ between HFpEF patients and healthy control
individuals (EC, YC). Likewise, no sign or symptom of
orthostatic hypotension was detected in HFpEF patients,
despite they presented with a 24% increment of baseline
IJV aspect ratio (a proxy for CVP (Keller et al. 2009;
Montero et al. 2016a)) but normal arterial blood pressure
compared with EC. Therefore, the present study demon-
strates that HFpEF patients may retain the control of
hemodynamic stability against sustained CVP elevation
and acute CVP curtailment with HUT, presumably
underpinned by a resetting of low-pressure baroreceptors
to operate at higher pressure levels.
Beyond swift hemodynamic responses driven by neural
reflexes, endocrine responses are capital to cope with sus-
tained orthostatic challenges. As aforementioned, afferent
signals from central baroreceptors regulate the production
of BV-regulating hormones, thereby modulating kidney
function according to the “fullness” of the intrathoracic
compartment (Segar and Moore 1968; Egan et al. 1984;
Bie et al. 1986; Sander-Jensen et al. 1986; Montero et al.
2016a). When gravity propels BV toward the lower
extremities, central baroreceptors are partially unloaded
and circulating levels of key hormones governing PV and
RBCV such as pro-ANP, vasopressin, the RAAS cascade,
and EPO, are altered in the direction of fluid retention
and enhanced erythropoiesis (Montero et al. 2016a). Sub-
sequent volumetric adaptations are essential to avoid the
circulatory collapse that would eventually ensue if only
cardiovascular adjustments were recruitable in the attempt
to preserve cardiac filling (Guyton 1957; Gauer and
Henry 1963). Consistent with this rationale, in this inves-
tigation HUT prompted changes in circulating proANP
(13 to 22%), copeptin (+13 to +35%), and aldos-
terone (+9 to +32%), collectively facilitating PV expan-
sion. No statistical difference was detected among groups.
In contrast, HUT did not alter circulating EPO in HFpEF
–30
–15
0
15
30
45
60
Time (min)
A
ld
os
te
ro
ne
(%
ch
an
ge
)
*
*
            *
*
*
*–30
–20
–10
0
10
20
30
Time (min)
pr
oA
N
P
(%
ch
an
ge
)
0
10
20
30
40
50
60
Time (min)
C
op
ep
tin
(%
ch
an
ge
) HFpEF
EC
YC
*
*
*
20 60 120 
20 60 120 20 60 120 
20 60 120 
–10
–5
0
5
10
15
Time (min)
EP
O
(%
ch
an
ge
) *
*
Figure 2. Endocrine responses to HUT in HFpEF patients and control individuals. Data are presented as mean  SEM. and control individuals.
Data was not available in YC for aldosterone and time “120”.* Significant change (P < 0.05) compared with baseline (supine). EC, elderly
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patients and EC, differing from the rise in EPO observed
in YC. Whilst speculative, the age-related impairment of
the hemodynamic regulation of EPO could contribute to
the prevalent RBCV deficit in the HFpEF population
(Montero et al. 2017), given that the prominent stimulus
for EPO synthesis, that is, the hypoxic drive, effectively
operates at very low hematocrit levels (Kurtz and Eckardt
1990; Le Hir et al. 1991; Roberts et al. 2000; Wenger and
Kurtz 2011). In fact, provided that pulmonary gas
exchange is not impaired, EPO production cannot be
spurred by hypoxia-dependent mechanisms unless RBCV
and hemoglobin mass are markedly reduced, particularly
when arterial oxygen content is preserved due to a con-
comitant reduction of PV as observed in heart failure
patients long-term treated with loop diuretics (Anand
et al. 1989; Feigenbaum et al. 2000; Bonfils et al. 2010), a
common prescription in our study population (Montero
and Flammer 2017). Furthermore, it should be noted that
baseline EPO levels were elevated in HFpEF patients and
presented higher variability compared with healthy con-
trol groups. This concurs with previous observations in
HF patients showing increased plasma EPO in direct rela-
tionship with disease severity (Volpe et al. 1994; George
et al. 2005). EPO levels in HF are also a function of
hemoglobin concentration, age, sex, and inflammation
(Montero et al. 2018), underpinning the complex patho-
physiology of HF. Indeed, increased baseline EPO may
have limited the responsiveness of EPO-producing cells to
HUT-related stimuli in the present study. Ultimately, the
hemodynamic regulation of EPO production in HFpEF
patients may be inadequate to cope with chronic heart
failure-related limitations to the erythropoietic process,
for example, hematopoietic bone marrow dysfunction and
secondary EPO resistance (Westenbrink et al. 2010;
Okonko et al. 2013).
The mechanisms underlying the absent EPO response
to reduced CVP in HFpEF and EC are uncertain. Aging is
inexorably associated with a progressive stiffening of the
circulatory system (Monahan et al. 2001) leading to
blunted baroreceptor firing rate attributed to restricted
changes in vessel circumference (Kingwell et al. 1995). In
consequence, specific baroreflex-endocrine signaling path-
ways that stimulate erythropoiesis may be altered with
advanced age. In this respect, vasopressin responses, pri-
marily dependent on high-pressure (aortic and carotid)
baroreceptors (Norsk et al. 1993; Thrasher and Keil
1998), are decreased during orthostatic stress in elderly
individuals (Rowe et al. 1982). Vasopressin, in parallel to
controlling water reabsorption, directly prompt EPO
secretion through the activation of V1a receptors(Engel
and Pagel 1995) expressed in the renal cortex and
medulla (Gozdz et al. 2002; Koshimizu et al. 2006). In
healthy young individuals, the increase in circulating EPO
induced by moderate HUT is strongly associated with the
concomitant increase in copeptin (Montero et al. 2016a).
In agreement with prior evidence in elderly individuals
(Rowe et al. 1982), the effect of HUT on copeptin was
seemingly attenuated and delayed in HFpEF patients and
EC. This could be partly attributed to the similarly
impaired central arterial distensibility in HFpEF patients
and EC (Montero et al. 2016b). Similar to the EPO
response, the effect of HUT on copeptin in EC and
HFpEF patients could also be influenced by elevated
copeptin basal levels, which as a matter of fact are
strongly associated with renal dysfunction and poor prog-
nosis in HFpEF patients (Hage et al. 2015). Furthermore,
vasopressin release might be inhibited with augmented
mean arterial pressure (Gabrielsen et al. 2000), as
observed herein in the elderly groups. Further experimen-
tal research is needed to establish whether baroreflex-
endocrine mechanisms may explain the age-dependent
impairment of the EPO response to HUT in the HFpEF
condition.
Limitations
First, findings arose from a moderate sample size of stable
HFpEF patients, mainly males, thus our conclusions
should be taken with caution. Likewise, control individu-
als did not present comorbidities or risk factors. There-
fore, a clear separation between HFpEF and additional
conditions cannot be ascertained. Larger prospective stud-
ies might buttress the present findings and contrast differ-
ent HFpEF phenotypes, comorbidities, risk factors, and
pharmacotherapies (Montero and Flammer 2017). Sec-
ond, kidney partial pressure of oxygen (PO2), a variable
regulating EPO production independently of central
hemodynamics, was not assessed. Nonetheless, the main
determinant of kidney PO2, that is, glomerular filtration
rate, was not altered during HUT in HFpEF patients and
control individuals. Third, smoking may have influenced
EPO levels (Eisenga et al. 2018) in the 3 HFpEF patients
who were smokers. The exclusion of these patients did
not affect the results of the study. Finally, we did not
include a control intervention for time since previous
studies indicate (i) a prevailing impact of HUT over the
circadian rhythm of BV-regulating hormones (Montero
et al. 2016a), and (ii) minimal or no diurnal fluctuation
of circulating EPO (Gunga et al. 1996; Roberts and Smith
1996).
Conclusion
The current study demonstrates that prolonged HUT elic-
its comparable central hemodynamic responses in HFpEF
patients and control individuals. In contrast, endocrine
ª 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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responses to reduced CVP comprising increases in
circulating EPO are absent in HFpEF patients and
age-matched elderly individuals, suggesting that the
hemodynamic regulation of EPO production is age-
dependent. The pathophysiological mechanisms underly-
ing these findings are speculative at present and will have
to be characterized in future studies.
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